There are also an emerging class of CNS active compounds that contain an amino group appended to a heterocyclic base structure (Figure 2 ), for example the Figure 2 . The structures of known CNS active compounds. [8] [9] [10] [11] [12] In our continuing project concerned with the discovery of new bioactive benzylisoquinoline derivatives, [13] [14] [15] the 2'-aminoalkyl-1-benzylisoquinoline compound 7 and the medium side ring analogues 8 were of interest. We report here our attempts to synthesise these compounds and the biological activities of four of these analogues on 48 different CNS receptors. Figure 3 . The targeted 1-benzylisoquinoline derivatives containing 2'-aminoalkyl substituents (7) and the medium sized ring targets (8) . Table 1 Synthesis of 2'-aminomethyl-1-benzylisoquinoline analogues by group of the bis-amine 31 into the corresponding aldehyde 32 was attempted using TsOH/CH 3 OH/H 2 O at rt to reflux temperature, however no product was obtained.
Alternatively, the amine 31 was heated in a solution of 10% aqueous HCl/MeOH at ) 2 ) had disappeared, however, the expected aldehyde signal in the  9-10 region was not observed. ESIMS analysis showed a MH + signal at m/z 415.0 which would correspond to the hemiacetal 34. The crude compound was subjected to the reductive amination conditions with NaCNBH 3 , however no identifiable products were obtained.
Alternatively (Scheme 5) , the aldehydes 15 and 16 were reductively coupled with methylamine to afford the corresponding benzylisoquinolines 36 and 37 in 71%
and 79% yield, respectively. The amines 36 and 37 subsequently underwent Nacylation with chloroacetyl chloride to give the corresponding -chloroacetamides 38
and 39 in good yields (72-80%). Hydrolysis of the N-TFA group of 38 and 39 exposed the free amino groups for an intramolecular S N 2 displacement of the chloride under basic conditions with triethylamine to provide the desired medium ring compounds 40 and 41 in moderate yields (46-57% over 2 steps). The 9-membered ring 40 was subjected to carbonyl reduction using lithium aluminium hydride to afford the corresponding cyclic amino compound 42 in 81% yield. Analysis of the • Scheme 5
In vitro CNS Receptor Binding Studies.
The in vitro testing was conducted at Cerep Corporation in France. Four 2'-aminoalkyl-1-benzylisoquinoline derivatives 11, 25, 26 and 27 were tested for biological activities on 48 different CNS receptors. 20 The activities were expressed as % inhibition of control specific binding (Table 2) , which is the measure of the direct inhibition activity of the tested drug exerted on the controlled ligand. Therefore the drug is considered active when the % inhibition of control specific binding is high at the CNS receptor type tested.
The CNS binding activities of the four derivatives 11, 25-27 are shown in Table 2 . All four compounds showed binding activities at the mu ( opiod receptor (MOP), with compound 11 having the highest mu receptor activity with 46% inhibition of the control (DAMGO) specific binding at 1 M concentration.
Compound 26 was tested at 10 M concentration and was shown to have binding activities against several receptors, most prominently at the muand kappa opiod (KOP) receptors, with inhibition activities of 52% and 40%, respectively. The IC 50 of these compounds are yet to be determined, but that of compound 11 and 27 would be estimated to be in the low micromolar range activities against the mureceptor.  Table 2 In vitro CNS receptor binding activities of compounds 11 and 25-27. Across the 48 CNS receptors, only the receptors with 25 % or more of inhibition activities are illustrated below. The muopiod receptor is one major class of opiod receptors which has been targeted for its analgesic properties.
21
Opiod agonists such as morphine exert their activities mainly at the mu opiod receptor and have been widely used in pain therapy. 21 Chronic morphine therapy, however, can produce unwanted side effects such as tolerance, respiratory suppression and constipation. 21 Muopiod antagonists are commonly used as a rescue medication to reverse these side effects as well as combating alcohol and narcotic addiction. [22] [23] Muopiod antagonists also have potential applications in the treatment of obesity, psychosis and Parkinson's disease. 22 Therefore, depending on their agonist or anatagonist properties, compounds 11 and 25-27 and their analogues could be used in pain treatment therapy, or for the treatment of narcotic addictions as well as obesity, psychosis and Parkinson's disease.
In conclusion, seven novel 2'-aminoalkyl-1-benzylisoquinoline analogues and three medium sized ring 1-benzylisoquinoline analogues were successfully synthesised. Four analogues 11, 25, 26 and 27 showed moderate to good inhibition of control specific binding activities at 1-10 M concentrations against the mureceptor.
Unfortunately, compounds 24, 28-29 and 40-42 were unable to be tested.
Experimental
Petrol refers to the fraction of petroleum spirit with a boiling point of 40-60C. General method for dihydroxylation. 17, 18 To a solution of the olefin in acetone was added potassium osmate dihydrate give an oil. The oil was purified by column chromatography (EtOAc) to afford the desired product. A solution of the olefin 9 (135 mg, 0.290 mmol) in acetone (3 mL) was treated as described above in the general dihydroxylation reaction procedure using A solution of the olefin 12 (120 mg, 0.255 mmol) in acetone (7 mL) was treated as described above in the general dihydroxylation reaction procedure using 
General method of reductive amination.
To a solution of the aldehyde and the amine in CH 3 CN was added NaCNBH 3 .
The reaction was stirred at RT for 20 min before glacial acetic acid was added to adjust the pH to ~ 6. The resulting solution was stirred for 18 h at RT. The CH 3 CN was evaporated and the residue was dissolved in CH 2 Cl 2 . The solution was washed subsequently with H 2 O (3 x), sat. Na 2 CO 3 , brine and dried (MgSO 4 ) to give an oil.
The oil was purified by column chromatography to afford the pure product.
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(morpholino)methylphenyl]methylisoquinoline (17).
A mixture of the aldehyde 22 (58 mg, 0.125 mmol), morpholine (0.10 mL, 1.16 mmol), CH 3 CN (15 mL) and NaCNBH 3 (10 mg, 0.162 mmol) was treated as described above in the general reductive amination reaction procedure to give an oil. 
General method for N-Trifluoroacetyl deprotection and reductive N-

Methylation.
The N-TFA protected amine was dissolved in a mixture of CH 3 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(morpholino)methyl phenyl]methyl-2-methylisoquinoline (24).
The N-TFA protected amine 17 (40 mg, 0.074 mmol) was treated as described above in the general N-TFA deprotection and reductive N-methylation reaction procedure by initially using K 2 CO 3 (50 mg, 0.370 mmol), CH 3 OH (5 mL) and H 2 O (1 mL), except it was stirred at 80 0 C for 3 h, then using 38 % formaldehyde (3 mL), CH 3 CN (3 mL) and NaCNBH 3 (6 mg, 0.096 mmol) to give an oil. 
(RS) 1-[2'-(Diethylamino)methyl-4',5'-dimethoxyphenyl]methyl-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline (26).
The N-TFA protected amine 19 (75 mg, 0.161 mmol) was treated as described above in the general N-TFA deprotection and reductive N-methylation reaction procedure by initially using K 2 CO 3 (109 mg, 0.810 mmol), CH 3 OH (2 mL) and H 2 O (1 mL), except it was stirred for 4 h and then using 38 % formaldehyde (3 mL), CH 3 CN (3 mL) and NaCNBH 3 (20 mg, 0.328 mmol) 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(2''-(isopropylamino)methyl)phenyl]methyl-2-methylisoquinoline (27).
The N-TFA protected amine 20 (60 mg, 0.136 mmol) was treated as described above in the general N-TFA deprotection and reductive N-methylation reaction procedure by initially using K 2 CO 3 (91 mg, 0.680 mmol), CH 3 OH (3 mL) and H 2 O (1 mL), except it was stirred for 4 h, and then using 38 % formaldehyde (3 mL), CH 3 CN (3 mL) and NaCNBH 3 (20 mg, 0.328 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(2'''-(pyrolidino)ethyl) phenyl]methyl-2-methylisoquinoline (28).
The N-TFA protected amine 22 (38 mg, 0.076 mmol) was treacted as described above in the general N-TFA deprotection and reductive N-methylation reaction procedure by using initially K 2 CO 3 (52 mg, 0.381 mmol), CH 3 OH (5 mL) and H 2 O (1 mL), then 38% formaldehyde (3 mL), CH 3 CN (3 mL) and NaCNBH 3 (10 mg, 0.164 2.52-2.30 (m, 8H, 2xH1'', 2xH2'', 2xH2''', 2xH5'''), 1.75 (t, 4H, J 3.9 Hz, 2xH3''', 2xH4'''). The N-TFA protected amine 23 (80 mg, 0.149 mmol) was treated as described above in the general N-TFA deprotection and reductive N-methylation reaction procedure by initially using K 2 CO 3 (100 mg, 0.735 mmol), CH 3 OH (5 mL) and H 2 O (1 mL), then 38% formaldehyde (3 mL), CH 3 CN (3 mL) and NaCNBH 3 (20 mg, 0.328 The aldehyde 15 was freshly generated from the diol 13 (139 mg, 0.278 mmol) as described in the general oxidative cleavage reaction procedure using a suspension of silica gel coated with NaIO 4 , using NaIO 4 (827 mg, 3.89 mmol), H 2 O (2 mL), silica gel (1.7 g) and CH 2 Cl 2 (5 mL). To the solution of the aldehyde 15 in CH 3 CN (4 mL) was added aminoacetaldehyde diethylacetal (487 mg, 3.67 mmol, 0.5 mL) and NaCNBH 3 (12 mg, 0.475 mmol). The reaction mixture was stirred at rt for 20 min and the pH was adjusted to ~ 6 using glacial acetic acid. The reaction mixture was stirred for 18 h at rt. The CH 3 CN was evaporated and the residue was dissolved in a mixture of CH 3 OH (10 mL) and H 2 O (3 mL). K 2 CO 3 (100 mg, 0.737 mmol) was added and the mixture was stirred at rt for 18 h. 4.26 (dd, 1H, J 8.7, 3.9 Hz, H1), 3.86 (s, 3H, , 3.83 (s, 3H, 3.81 (s, 3H, 2H, 2xH3), 3.79 (s, 3H, , 3.37 (s, 6H, 2 x OCH 3 ), 1H, H7'), 3.11 (dd, 1H, J 12.6, 4.2 Hz, H1''), 2H, H7', H1''), 2.80 (dd, 2H, J 5.3, 2.1 Hz, 2xH1'''), 2H, 2xH4 The synthesis of the tittle compound 41 was carried out using the conditions described above for the synthesis of 40 starting with compound 39 (63 mg, 0.108 mmol), CH 3 OH (3 mL), H 2 O (1 mL) and K 2 CO 3 (112 mg, 0.825 mmol). This was followed by intramolecular cyclisation using CH 2 Cl 2 (10 mL) and triethylamine (0.3 mL) to
give an oil which was purified by column chromatography (EtOAc) 
